- Patients with advanced NSCLC had significantly longer OS with first-line nivolumab+ipilimumab than chemotherapy, regardless of PD-L1 expression levels.
Why this matters
- Prior studies had found an OS benefit from nivolumab+ipilimumab in melanoma and renal cell carcinoma, but efficacy in NSCLC was unclear.
- Preliminary report from the randomized, phase 3 CheckMate 227 trial.
- Patients with advanced NSCLC and PD-L1 expression levels of ≥1% or
- Funding: Bristol-Myers Squibb; Ono Pharmaceutical.
- In the overall population, median OS was higher with nivolumab+ipilimumab vs chemotherapy (17.1 vs 13.9 months).
- Combination therapy offered better median OS than chemotherapy in patients with:
- PD-L1 ≥1%: 17.1 vs 14.9 months (P=.007); HRdeath=0.62 (95% CI, 0.48-0.78).
- PD-L1 progression/death, 0.73, P=.0007).
- At 2 years, nivolumab+ipilimumab offered better median duration of response (17.1 vs 13.9 months) and OS (40.1% vs 29.7%) vs chemotherapy in all patients, regardless of PD-L1 expression.
- Serious any-grade adverse events were more common with combination immunotherapy (24.5% vs 13.9%), as were events leading to discontinuation (18.1% vs 9.1%).
- Open-label trial.